Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
A team of researchers have published in the International Journal of Oncology that RITA, a drug able to reactivate the oncosuppressor function of p53, could be an effective strategy to treat glioblastoma.
Glioblastoma is the most prevalent and also the most lethal type of brain tumor in adults, with no curative treatment currently available.
Glioblastoma is an incurable type of brain tumor that is frequently associated with mutations in the epidermal growth factor receptor.
Using human cancer cells, tumor and blood samples from cancer patients, researchers at Johns Hopkins Medicine have uncovered the role of a neurotransmitter in the spread of aggressive cancers. Neurotransmitters are chemical "messengers" that transmit impulses from neurons to other target cells.
Scientists from Far Eastern Federal University in cooperation with colleagues from Blokhin Russian Cancer Research Center, Switzerland, and Sweden for the first time studied proteins, which constitute WNT signaling pathway of the cancer stem cells of glioblastoma multiforme (GBM CD133+ CSCs), one of the most aggressive brain tumors.
Photodynamic diagnosis using 5-aminolevulinic acid (5-ALA) is now widely used for neurosurgical resection of brain tumors.
University at Buffalo researchers have developed a new method to more accurately predict tumor growth rates, a crucial statistic used to schedule screenings and set dosing regimens in cancer treatment.
A new study led by Massachusetts General Hospital (MGH) investigators finds that radiation therapy may increase the uptake of therapeutic nanoparticles by glioblastomas, raising the possibility of using both growth-factor-targeted and immune-system-based therapies against the deadly brain tumor.
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will showcase ongoing studies and data on chimeric antigen receptor T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.
Ludwig Cancer Research released today the full breadth of findings to be presented by Ludwig researchers at this year's American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Ga., March 29 - April 3, 2019.
Advances in genetics and genomics have taught us that every single tumor is different, and yet most standard therapies treat them all in the same way, limiting the effectiveness of treatments offered to many cancer patients.
Researchers have engineered "antibody-like" T cell receptors that can specifically stick to cells infected with cytomegalovirus, or CMV, a virus that causes lifelong infection in more than half of all adults by age 40.
With their ability to treat a wide a variety of diseases, spherical nucleic acids (SNAs) are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components.
Cancer researchers at the University of Bonn have reported significant progress in the treatment of glioblastoma. About one third of all patients suffer from a particular variant of this most common and aggressive brain tumor.
Columbia researchers have learned why some glioblastomas--the most common type of brain cancer--respond to immunotherapy. The findings could help identify patients who are most likely to benefit from treatment with immunotherapy drugs and lead to the development of more broadly effective treatments.
A UCLA-led study suggests that for people with recurrent glioblastoma, administering an immunotherapy drug before surgery is more effective than using the drug afterward.
Around a glioblastoma, a very aggressive brain tumor, cells of the human immune system start helping the tumor instead of attacking it. To do research on what happens in the interaction of these cells, scientists of the University of Twente now created a 3D-bioprinted mini model of the brain.
A breakthrough for brain tumor drug development and personalized medicine published today in Nature Scientific Reports.
Following a California Institute for Regenerative Medicine Independent Citizens Oversight Committee meeting held last week, University of California, Irvine researchers learned they will receive $6 million in funding to support the continued development of a promising new treatment for Huntington's disease
A study led by investigators from Massachusetts General Hospital (MGH) and the University of Cyprus reveals details of a way the dangerous brain tumors called glioblastomas resist the effects of antiangiogenic drugs designed to cut off their blood supply.